Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma. Review uri icon

Overview

abstract

  • The various clinical trials suggest that the qualitative and quantitative responses of patients with Stage D prostatic carcinoma to antiandrogens are similar to those achieved with conventional endocrine therapy. These antiandrogens appear generally safe and many avoid the increased risks of cardiovascular or thromboembolic complications seen with estrogen therapy. Further, flutamide appears to have a lesser adverse effect on libido and sexual potency than do alternative therapies. Antiandrogens offer an alternative mode of therapy for previously untreated patients with advanced prostatic cancer but have produced no convincing benefits in hormonally refractory patients.

publication date

  • January 1, 1988

Research

keywords

  • Androgen Antagonists
  • Anilides
  • Antineoplastic Agents
  • Flutamide
  • Prostatic Neoplasms

Identity

Scopus Document Identifier

  • 0024149460

Digital Object Identifier (DOI)

  • 10.1007/978-1-4613-1731-9_9

PubMed ID

  • 2908604

Additional Document Info

volume

  • 39